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1Enhancing the tolerance of myocardium to the lethal consequences of ischemia and 
reperfusion, especially myocardial necrosis (infarction) remains a highly desirable 
therapeutic goal. While recent advances in primary prevention and timely reperfusion 
have reduced early mortality from acute myocardial infarction (AMI), long term 
prognosis is directly related to the extent of tissue necrosis sustained during the 
index coronary occlusion/reperfusion insult. During the last three decades or so, 
sustained exploration of the endogenous physiological signalling cascades recruited 
to enhance tolerance, has demonstrated that there are many components to the 
multifaceted conditioning paradigms (pre conditioning and post conditioning). One 
such component is guanosine-3’, 5’-cyclic monophosphate (cyclic guanosine 
monophosphate, cGMP), a cyclic nucleotide responsible for eliciting many potentially 
cardioprotective actions. 
1. Historical background 
cGMP is an intracellular second messenger produced from the purine nucleotide 
guanosine triphosphate (GTP) in a reaction catalysed by cytosolic soluble guanylyl 
cyclase (sGC) or membrane associated particulate guanylyl cyclase (pGC). 
Following the discovery of cAMP in the late 1950s1, cGMP, was confirmed to be a 
physiological mediator when Price et al. isolated it from rat urine in 19632 and 
Sutherland’s laboratory demonstrated that steroid, thyroid and pituitary hormones 
affected urinary excretion of cGMP. Fifty years after its discovery, cGMP is now 
established as a ubiquitous second messenger, mediating a large variety of 
physiological processes. 
2Within the cardiovascular system, cGMP is well-established as an important 
pharmacological target. Indeed, targeting cGMP signalling for the therapeutic 
treatment of cardiovascular disease is not a recent discovery. T Lauder Brunton’s 
description of the effects of amyl nitrite in angina pectoris in 1867 and William 
Murrell’s subsequent description of the effects of glyceryl trinitrate (nitroglycerin) in 
1879 preceded any understanding of the mechanism of action by more than a 
century.3 Following the description of a (then) unidentified endothelium-derived 
relaxing factor (EDRF) in the early 1980’s4,5 it was demonstrated that EDRF 
increases cGMP synthesis in isolated blood vessels.6,7 The subsequent identification 
of EDRF as nitric oxide (NO)8 and its association with guanylyl cyclase activity and 
cGMP synthesis7 opened up an area of biology with huge potential for 
pharmacological exploitation, especially in the cardiovascular system. In the early 
1990’s cGMP was shown to be an important cyclic nucleotide in affording the 
preconditioned state in rabbit myocardium.9
In the late 1980s and early 1990s, the sequential discovery of a series of peptide 
mediators produced within the cardiovascular system, called natriuretic peptides, 
opened up a new dimension in cGMP signalling. The major members of this family - 
in order of discovery; atrial natriuretic peptide (ANP), brain- or B-type natriuretic 
peptide (BNP) and C-type natriuretic peptide (CNP) – all elicit their biological actions, 
at least in part, through elevation of intracellular cGMP. The natriuretic peptide 
membrane-associated receptors, NPR-A and NPR-B, contain guanylyl cyclase 
domains capable of catalysing the conversion of GTP to cGMP. This particulate 
guanylyl cyclase (pGC) activity is, as far as we know, uniquely activated by the 
natriuretic peptide family of mediators which include ANP, BNP, CNP and the related 
3guanylins and atriopeptins. This further dimension to cGMP regulation in the 
cardiovascular system provides additional complexity and opportunities for 
therapeutic manipulation. 
Over the last thirty years extensive investigation has focused on the physiological 
roles and regulation of the cGMP pathway, its disruption in various diseases and its 
therapeutic “druggability”. In this review we explore the extensive literature focusing 
on myocardial cytoprotection against ischaemia-reperfusion injury. We consider the 
basic research and consequent clinical studies that have followed with particular 
reference to the clinical treatment of acute myocardial infarction (AMI). 
2. Production and localisation of cGMP 
cGMP production is mediated by two distinct guanylyl cyclases, which are spatially 
discrete within the cell. pGC is described as membrane associated and is confined to 
the plasma membrane, connected to the extracellular ligand binding domain via a 
kinase homology region. ANP shows the highest affinity for the NPR-A receptor, 
whilst BNP is 10-fold less potent.10 CNP is the primary ligand for NPR-B, stimulating 
guanylyl cyclase with 50-500-fold greater affinity than ANP and BNP (Figure 1).11
sGC is found in the cytoplasmic domain, catalysing the production of cGMP primarily 
through the binding of the endogenous ligand NO. sGC is a heterodimeric haem 
protein consisting of both an alpha and beta subunit. To date, two alpha and two beta 
isoforms have been identified.12,13 The α1β1 protein has been most extensively 
researched and is found in most tissues, including the kidney, brain, heart and 
4vascular tissue.14 A heterodimer consisting of both subunits is essential to form the 
catalytically active sGC.15,16 The N-terminal histidine 105 haem binding site of the β 
subunit forms the basis of the NO-sensing region, which when occupied by NO leads 
to a 200-fold increase in the synthesis of cGMP (Figure 1).17 Endogenous CO has 
also been shown to activate sGC, but producing only a 4-fold increase in activity.18
cGMP activity is governed by specific cGMP-binding motifs on target proteins and its 
highly regulated degradation by phosphodiesterease (PDE’s). cGMP-dependent 
protein kinase (PKG) represents the primary cGMP mediator which phosphorylates 
target proteins. PKG-I shares its allosteric cGMP-binding motif with PKA (50-fold 
lower selectivity than cAMP) and a second cGMP effector, the cyclic 
nucleotide-gated (CNG) ion channel. The second binding motif occurs only in the 
cGMP-regulated PDE’s. Indeed, it is this complex combination of effectors that tightly 
regulates cGMP signalling. PKG, PKA and CNG channels are co-localised with 
effector proteins in different cell types resulting in differing responses to elevated 
cGMP levels. For example PKG is co localised with phospholamban (PLB) and the 
IP3 receptor in the sarcoplasmic reticulum in smooth muscle cells. In contrast PKA is 
co localised with PLB and IP3 in cardiac myocytes eliciting differing responses to 
elevation of cGMP. Disruption of cGMP signalling has been identified in many 
aspects of cardiovascular function and disease including platelet aggregation, 
inotropy, cell growth/proliferation and apoptosis, all of which rely on tightly regulated 
and specific signalling. 
Hydrolysis of cGMP to 5’GMP occurs through PDE catalytic activity. There are ten 
families of mammalian PDE, four of which hydrolyse both cGMP and cAMP (1, 2, 3 
and 10) and three which are specific for cGMP (5, 6 and 9). Specific targeting 
sequences found in PDE’s traffic them to specific proteins leading to their being 
5expressed in discrete subcellular locations. The net effect of this is that the 
intracellular concentration of cGMP varies within different subcellular compartments. 
Of the PDE isozymes, PDE 2 and 5 are of particular interest because they have been 
demonstrated to show distinct regulation of specific cGMP subcellular concentrations 
as a result of pGC and sGC mediated production respectively.19 Thus, there is a 
multifaceted approach to regulating cGMP and its downstream effectors. In this 
review, we will focus on potential therapeutic targets that can augment the 
production, distribution, localisation and metabolism of cGMP to limit the cytotoxic 
affects of myocardial ischaemia-reperfusion injury, resulting in myocardial necrosis. 
3. NO, Nitrite and Nitrate 
Nitric oxide 
NO is a gaseous autacoid formed by the action of nitric oxide synthase (NOS) on 
L-arginine, NADPH and molecular oxygen.20 NO is a critical regulator of 
cardiovascular homeostasis.20 Under physiological conditions, NOS mediated NO 
formation is permitted due to uncompromised delivery of substrate and molecular 
oxygen. However in disease states such as coronary artery disease characterized by 
abnormally low oxygen and high energy phosphate depletion, endothelial derived NO 
bioavailability as a result is severely compromised.21 Acute and chronic hypoxia 
down-regulates endothelial NOS (eNOS) at mRNA and protein levels in various 
cardiovascular tissues.22 For a comprehensive review of NO in ischaemic heart 
disease we direct the reader to Rassaf et al.23 and Ferdinandy and Schulz24.
6Nitrate and nitrite as a potential NO reserve 
An alternative pathway for NO formation involving nitrate and nitrite, which 
predominates when tissue oxygen tension is low, has been described in mammals,.25
Nitrate (NO3
-) and nitrite (NO2
-) can be considered reservoirs for NO when 
NOS-dependent NO levels are insufficient to maintain cellular homeostasis.21 NO3
-
and NO2
- can be reduced in sequential steps by enzymatic and non-enzymatic 
mechanisms creating new pools of NO with the potential to activate the 
sGC/cGMP/PKG pathway or by other processes that are distinct from this classical 
route of intracellular signalling.21 The reaction of NO with oxyhaemoglobin leads to 
the production of nitrate and the formation of methaemoglobin.26,27 Green leafy 
vegetables are a major source of NO capable of delivering more nitrate than all the 
NOS isoforms combined.21,28 NO2
- is formed following auto-oxidation of NO, non-
enzymatically by deoxyhaemoglobin29, and by the enzymes ceruloplasmin, xanthine 
oxidoreductase and aldehyde oxidase.30 The mitochondrion has been shown to be a 
source of NO2
-, and to exhibit nitrite reductase activity.31 Plasma nitrate concentration 
in humans is approximately two orders of magnitude greater than that of nitrite 
ranging from 20-50 μM32, plasma nitrite concentrations in fasting humans are 
typically within the range 50-500 nM.33-36
Both NO3
- and NO2
- were considered terminal products of NO synthesis, but are now 
recognized as reserve sources for NO production, especially under conditions of 
hypoxia.31 NO derived particularly from nitrite has been shown to modify proteins and 
redox state37, which may be determinant factors in facilitating cytoprotection in 
models of ischaemia-reperfusion injury in the heart and other organs38. The precise 
7mechanism by which NO2
- is reduced to NO or whether NO is released from 
erythrocytes to promote vascular smooth muscle relaxation is currently unclear.31
Nitrite-derived NO39 and dinitrogen trioxide (N2O3)
40 have been proposed as nitrogen 
oxide species responsible for promoting NOS-independent vasodilatation in humans. 
Lunberg and colleagues21 suggest that both species form in the circulation, the 
former liberated by the reaction of nitrite with deoxyhaemoglobin, and the latter from 
the reaction of nitrite-bound methaemaglobin and NO, forming a nitrogen dioxide 
radical which then reacts with free NO to form N2O3. 
Nitrate, nitrite and nitric oxide signal transduction mechanisms: cGMP vs 
S-nitrosylation 
The mechanisms by which nitrate and nitrite are converted to NO have already been 
highlighted; it is presumed that this pool of NO is capable of activating the same 
intracellular pathways as NOS-derived NO. NO stimulates sGC leading to the 
generation of cGMP, thereby affecting downstream mechanisms that modulate cell 
function. This classical form of NO signaling has been discussed extensively in 
comprehensive reviews.20,41 NO derived from inducible NOS (iNOS) has a pertinent 
role in regulating and contributing to signalling associated with oxidative stress in 
pathological states including inflammation. However the numerous intricate 
mechanisms and processes involved are beyond the scope of this review. We would 
refer readers to excellent reviews by Pfeilschifter et al42, Danson et al43, and Klein44
for a fuller examination. 
8There is growing interest in another form of NO signaling independent of sGC. This 
involves modification of protein thiol groups. S-nitrosylation implies the binding of NO 
to cysteine residues, altering the stability, binding, activity, localization and 
irreversible oxidation of cysteine rich proteins which are numerous.37,45,46 For 
example, s-nitrosylation increases sarcoplasmic/endoplasmic reticulum ATPase 
(SERCA) activity47, increases connexin 43 gap junction communication48 and inhibits 
phosphatase and tensin homolog (PTEN) activity49- preventing inhibition of PI3K/Akt, 
which are significant factors in the context of myocardial ischaemia-reperfusion and 
cardioprotection.37 Ischaemic preconditioning effected by brief periods of ischaemia 
and reperfusion prior to a sustained ischaemic insult is cardioprotective. Mouse 
hearts subjected to this form of cardioprotective intervention were found to have 
increased s-nitrosylation of L-type calcium channels and SERCA decreasing 
intracellular calcium load, and S-nitrosylation of the F1-ATPase limiting ATP 
breakdown.47
The cytoprotective action of nitrite 
Organic and inorganic nitrate and nitrite therapy has many beneficial effects in the 
cardiovascular system. Numerous studies during the last two decades have 
examined the protective actions of organic nitrates and other NO-donor compounds 
in models of cardioprotection against ischaemia–reperfusion injury and have 
demonstrated the ability of the acutely administered agents to limit infarct size. 
Preliminary data has demonstrated that nitroglycerin can limit infarct size in isolated 
rat hearts when administered during early reperfusion.50 More recently however, the 
potential of inorganic nitrite and naturally occurring dietary nitrite as cardioprotective 
9sources of NO has been examined. Sodium nitrite (10-100 μM) reduced infarct size 
by some 70%, in the rat isolated heart.51 The protective effect of nitrite given for the 
full duration of global ischaemia but not reperfusion, was reversed by the 
NO-scavenger carboxy-PTIO, suggesting that nitrite mediated cardioprotection is in 
part NO-dependent.51 Nitrite cardioprotection appears to be NOS-independent as it 
was shown that sodium nitrite limitation of infarct size in a mouse model was still 
present during pharmacological NOS inhibition or in eNOS knockout mice.52 Other 
studies implicate xanthine oxidase activation and KATP channel opening in sodium 
nitrite-induced infarct size limitation in the rat heart in vivo and ex vivo.51,53 There is 
evidence to suggest that nitrite-derived NO S-nitrosylates mitochondrion complex-1 
during ischaemia-reperfusion, delaying mitochondrial permeability transition pore 
(mPTP) opening, ROS formation and cytochrome c release, and ATP depletion, thus 
conferring cardioprotection. Shiva and colleagues54 found that sodium nitrite given 24 
hr prior to ischaemia or acutely prior to reperfusion caused a marked reduction in 
infarct size in mouse hearts. Furthermore, it was demonstrated that sodium nitrite 
improves mitochondrial respiration following hypoxia in a concentration-dependent 
manner and delayed mPTP opening and cytochrome c release in isolated 
mitochondria subjected to hypoxia and reoxygenation.54 In contrast to these data it 
has been demonstrated that NO can inhibit cytochrome c oxidase (complex IV) 
activity, in mitochondria isolated from rat brain55 and skeletal muscle56 following 
incubation with SNP and GSNO respectively. 
Bryan and co-workers57 found that mice given free access to chow and water 
supplemented with sodium nitrite for 7 days were more resistant to myocardial 
ischaemia-reperfusion injury, compared to mice on a standard diet, displaying a 48% 
relative reduction in infarct size compare to mice that did not receive sodium nitrite.57
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Furthermore, dietary sodium nitrite significantly increased plasma and tissue RXNO 
products, for example S-nitrosothiols and nitrosoproteins, increased steady-state 
concentrations of nitrate and nitrite, and nitrosyl-haem products.57 These hallmark 
features are likely to be very important in conferring nitrite protection of ischaemic 
myocardium. Most recently it has been demonstrated that acute ingestion of dietary 
nitrate in the form of beetroot juice elevated circulating nitrate and nitrite levels in 
humans and elevated platelet cGMP levels in healthy male subjects only.58 Although 
this evidence is not associated with cardiovascular cytoprotection, it highlights the 
potential for dietary or supplemented nitrite as a credible mechanism for cGMP 
elevation. Previously the authors demonstrated that beetroot juice lowered blood 
pressure in healthy volunteers, elevating plasma NO2
- and cGMP levels.59
Pluta and colleagues60 examined the safety and feasibility of long-term NO2
- therapy 
in healthy volunteers administered sodium nitrite intravenously for 48 h. Cardiac NO3
-
, NO2
- and S-nitrosothiol levels in plasma increased in all subjects and returned to 
pre-infusion baseline levels within 12 h. The authors concluded that prolonged NO2
-
iv. infusion below the maximal tolerated dose is safe for use in treatment of major 
diseases including ischaemic heart disease. Side effects were limited to 
asymptomatic transient decreases in arterial blood pressure and asymptomatic 
increases in methaemoglobin. Indeed, the Nitrites In Acute Myocardial Infarction 
(NIAMI) trial is a placebo-controlled, double-blind, phase-2 clinical trial that aims to 
determine whether a 5 min iv infusion of sodium nitrite (14 μmol/mL) just prior to PCI 
can reduce infarct size and associated enzyme biomarkers including creatine kinase 
and troponin I, in patients presenting with ST-elevation MI (STEMI).61 Other 
endpoints include left ventricular ejection fraction and end diastolic volume at one 
11
week and six months after MI, and infarct size measured by magnetic resonance 
imaging at six months post MI.61 This multi-centre clinical study is the first 
investigating whether sodium nitrite infusion can reduce myocardial infarct size in 
man. This study may provide a significant platform for establishing sodium nitrite as 
first-line therapy in the clinical treatment of AMI. 
Receptor mediated NOS activation 
Many receptors have been linked to PI3K/Akt/eNOS signalling and elevation of 
intracellular NO including bradykinin, adenosine and opioid peptide receptors. Most 
recently β3-AR stimulation (see Figure 2) has been demonstrated to stimulate NO 
generation via eNOS in the left and right human myocardium, which is blocked in LV 
by the PI3K inhibitor LY294002.62 Aragon and colleagues63 recently demonstrated 
that β3-AR stimulation limits infarct size when administered at reperfusion in mice. 
This protection was accompanied by an elevation in eNOS-PSer1177 and elevated 
nNOS levels. Whether this protection is mediated by sGC/cGMP signalling or 
possible inhibition of mitochondrial respiration and xanthine oxidase64 remains to be 
elucidated. 
4. NO-independent stimulation/activation of sGC 
In addition to elevating cGMP via manipulation of NO, targeting sGC directly has 
become tractable in recent years. In this section we discuss the redox that sGC 
exists in, how the different redox states can be specifically targeted and the 
possibility of utilising CO as an alternative ligand. 
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Soluble guanylyl cyclase redox 
The rate of reaction in physiological conditions is regulated by diffusion; however 
complex redox equilibrium of sGC exists, identifying challenges in successfully 
targeting this pathway. It is now well accepted that sGC can exist in three different 
forms depending on the redox state of the central haem group65 The reduced 
(ferrous) haem group is critical for NO-sensing and stimulation of the enzyme. The 
oxidised (ferric) form is insensitive to NO, and appears to be physiologically 
unimportant in cGMP signalling. In addition a haem-free state exists, which, like the 
oxidised state, does not elicit enzymatic activity via NO.66 Identification of the three 
states of sGC has led to proposals that a redox shift occurs in pathological 
conditions. A shift in redox state from the ferrous to ferric state is associated with 
oxidative stress and production of ROS. This has been identified as one of several 
mechanisms in which the sGC/NO signalling pathway can be disrupted. Stasch et 
al.67 confirmed the presence of a sGC indistinguishable from the oxidised form of 
sGC found in vitro, in rat aorta, porcine pulmonary arterial endothelial cells and 
human platelets. 
Direct cGMP targeting 
Increasing intracellular concentration of cGMP has been shown to reduce myocyte 
contractility during reperfusion by inhibition of Na+/Ca2+ exchange and activation of 
SERCA via PKG mediated phosphorylation of PLB.68 PKG has also been shown to 
activate BKCa channels which when inhibited at reperfusion abolish protection 
afforded by upstream targets of cGMP.69
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D’Souza et al.70 reported that low concentrations of 8-Br-cGMP, a synthetic cGMP 
analogue given just prior to ischaemia through to early reperfusion limited infarct size 
in a rat isolated heart model. It was later shown that 8-Br-cGMP also produced infarct 
limitation when given at reperfusion, reducing infarct size by 40 % compared to 
control hearts.71 These data demonstrated that targeting cGMP/PKG directly could 
afford infarct limitation mediated by elevating cGMP. 8-Br-cGMP has been reported 
to activate p38 MAPK in isolated adult rat cardiomyocytes, but not Erk1/2 suggesting 
further components of the cytoprotective mechanism.72
sGC stimulating compounds 
The phenomenon of “nitrate tolerance” (tachyphylaxis to the vasodilator effects of 
organic NO donors) drove the discovery from the 1990s onwards of compounds that 
can initiate the sGC/cGMP pathway independently of NO or when bioavailability of 
NO is low. Ko et al. 73 described an indazole derivative, YC-1 (5-[1-(phenylmethyl)-
1H-indazol-3-yl]-2-furanmethanol), later described as the first NO-independent, 
haem-dependent stimulator of sGC.74 Subsequently, structurally related compounds 
were discovered that stimulate sGC, including BAY 41-2272 (3-(4-amino-5-
cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine) and 
BAY 63-2521/Riociguat (methyl N-[4,6-diamino-2-[1-[(2-fluorophenyl)methyl]-1H-
pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminate)75, (see Table 1) The 
mechanisms by which these compounds stimulate the activation of sGC are complex 
and go beyond the scope of this review.73,75,76 However their use has been 
investigated in pathological conditions where NO formation is compromised or when 
nitrate tolerance has developed.77
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sGC activating compounds 
A second distinct class of sGC modulating compounds, described as sGC activators 
was subsequently discovered. High throughput screening revealed several 
aminodicarboxylic acids including BAY 58-2667 (4-(4-carboxybutyl)(2-((4-
phenethylbenzol) oxy)phenethyl)amino)methyl)benzoic acid). Described as the first 
and most potent NO-independent, haem-independent sGC activator, Stasch et al. 78
demonstrated that BAY 58-2667 activated sGC even after it had been oxidised by the 
sGC inhibitor ODQ, or even after losing its haem group completely. This class of 
compounds has become favoured for use in the exploration of pathological diseases 
as they target the oxidised (pathological) state of the enzyme. In light of the proposed 
shift towards the oxidised and haem-free states under conditions of oxidative stress 
these compounds have been utilised in experimental models of 
ischaemia-reperfusion where oxidant conditions are well documented. Investigation 
of the chemistry and pharmacology of these compounds demonstrates that sGC 
activation goes beyond NO binding to the haem site on the β subunit. 
Specific sGC targeting 
Krieg et al.79 demonstrated significant infarct reduction in the rat heart when the sGC 
activator BAY 58-2667 was given at reperfusion following 30 min global ischaemia. 
They reported an elevation in cGMP levels in hearts perfused with the activator 40 
times greater than in control hearts and further demonstrated that infusion of 
BAY 58-2667 in open chest in situ rabbits following left coronary artery occlusion 
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limited infarct size by 40%. The protection was independent of NO, but dependent on 
PKG and mKATP signalling. In a similar model Cohen et al.
80 reported reduction in 
infarct size of 54 %. Interestingly the protection in that study was abrogated in the 
presence of a NOS inhibitor, an observation not concordant with the literature 
describing BAY 58-2667’s mechanism of action.78 Most recently Salloum et al.81 have 
demonstrated that BAY 58-2667 can limit infarct size when administered pre- or 
post-ischaemically in adult rabbits. They further suggested that PKG activity was 
increased following perfusion and interestingly H2S levels were elevated, abrogated 
by the PKG inhibitor KT5823. These data corroborate the most recent study which 
demonstrates that BAY 58-2667 limited infarct size at reperfusion in mouse. This 
protective effect was abrogated when the same treatment protocol was utilised in 
cardiomyocyte specific PKG-I knockout mice.82 Work from our own laboratory has 
demonstrated that perfusion of a structurally similar sGC activator BAY 60-2770 
could afford infarct limitation when perfused during reperfusion in an isolated rat 
heart model of regional ischaemia.83 This protection was not blocked by concomitant 
perfusion of ODQ, a haem site oxidiser. These data demonstrate that the ferric form 
of sGC is present in rabbit, rat and mouse myocardium during ischaemia and early 
reperfusion as an elevation in cGMP was measured following perfusion of the sGC 
activator in this setting. 
Haem oxygenase and CORMs 
The microsomal enzyme haem oxygenase (HO) catalyses the degradation of haem 
to CO, producing bilirubin and iron as co-products. HO-1 is not constitutively present 
but can be activated under many pathological stimuli, including those present during 
16
ischaemia-reperfusion such as oxidative stress and hypoxia.84 Although CO 
mediated activation of sGC only elicits small increases in catalytic activity, the 
antioxidants NAC and ALF were able to limit infarct size in diabetic rats, which was 
abrogated by HO-1 inhibition.85 cGMP levels were shown to be elevated in the aorta 
of spontaneously hypertensive rats following administration of the same HO-1 
inducing agent, hemin. Induction of HO-1 by CO releasing molecules (CORMS) has 
been shown to be cytoprotective when administered prior to ischaemia-reperfusion.86
The authors reported that the protection observed is comparable to that seen in 
classical late phase pre-conditioning; protection was conferred in part by recruiting 
HO-1. Taken together these studies demonstrate that HO/CO/sGC/cGMP signalling 
is impaired under pathological conditions in the myocardium, offering an additional 
target to afford cytoprotection (Figure 2). 
5. Natriuretic peptide signalling 
Natriuretic peptides as an indicator of infarct size
NPs play a fundamental role in cardiovascular homeostasis, their release being 
primarily regulated by pressure overload and myocardial stretch. In 1991, Mukoyama
et al.87 reported for the first time that BNP levels were elevated during myocardial 
infarction. It was later reported that elevation of BNP correlates with ischaemia 
severity.88,89 Since then several experimental studies have documented elevation of 
ANP90-92 and BNP70,93 in models of myocardial ischaemia. Most recently, numerous 
clinical studies confirmed the usefulness of measuring BNP levels in patients 
presenting with STEMI, and suggest that they are a good indicator of prognosis and 
infarct size.94-96
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Natriuretic peptides at reperfusion
Several studies have identified that NPs administered at reperfusion afford protection 
in both rat and rabbit models of ischaemia-reperfusion. Yang et al.97 reported that 
administration of ANP just prior to reperfusion limited infarct size in the rabbit heart. 
They also demonstrated that the protection afforded required KATP activity as 
inhibition of the channel with 5-HD abrogated the protective effects of ANP. BNP was 
also shown to limit infarct size in an in situ rat heart model, limiting infarct size in a 
concentration dependent manner.98 Our laboratory reported similar results in an ex 
vivo rat heart model, demonstrating concentration dependent infarct limitation with 
BNP, which like previous studies was dependent on KATP channel activity
69. 
Furthermore, we reported that NPs could play a role in post-conditioning mediated 
protection as the non-specific NPR-A/NPR-B antagonist isatin abolished the infarct 
limitation afforded by a 6 x 10 sec post-conditioning protocol in the rat heart.69 In a 
cell viability assay it has been reported that along with the sGC activator SNAP, BNP 
can limit cell death via common downstream signalling pathway involving elevated 
PKG.99 Most recently, George et al.100 reported that perfusion of BNP for 7 days post 
AMI significantly improved LV function and decreased LV remodelling in the rat heart. 
ANP was administered to patients in the J-WIND clinical trial in which infarct size 
measured by creatine kinase was accessed. Reported outcomes of the trial 
suggested that patients receiving ANP had lower infarct size, fewer reperfusion 
injuries and better outcomes than controls101 (Table 2). 
Alternative natriuretic peptide signalling mediates infarct limitation
18
Infarct limitation afforded by NPs has been demonstrated to require KATP activity as 
described above. It has also been demonstrated that protection is mediated by 
elevation of cGMP and distal PKG targets converging on the same effectors as 
NO/sGC signalling, i.e. regulating calcium via PLB and L-type calcium channels and 
potassium efflux through the KATP channel.
41,70,102
Other signalling pathways have been suggested to play a part in NP mediated infarct 
limitation. D’Souza et al.103 reported that concomitant perfusion of L-NAME prior to 
LDCA occlusion in the rat heart abrogated the protection afforded by BNP alone. 
Similarly, perfusion of ODQ abolished BNP induced infarct limitation103. These results 
suggested that activation of NOS and sGC are required to afford BNP protection. 
Whether cGMP generated by pGC, sGC or both was needed to afford BNP 
protection remains unclear. However these intriguing observations raise the 
possibility that NP-induced cardioprotection may be mediated through mechanisms 
that are more complex than activation of NPR-A alone. 
Similar observations were made in a reperfusion targeted treatment by Ren et al.98, 
who report that L-NAME reversed the protection afforded by BNP when given just 
prior to and throughout reperfusion in an in situ rat heart model. This was supported 
by Western blotting analysis that demonstrated that a cardioprotective dose of BNP 
significantly increased eNOS expression. These results were corroborated by our 
laboratory when L-NAME administered at reperfusion in an ex vivo rat heart model 
abrogated BNP infarct limitation.69 In an isolated perfused rabbit heart model, Yang 
et al.97 demonstrated that the upstream activators of eNOS are also essential for 
ANP mediated protection. cGMP has been thought to elicit its cytoprotective actions 
through recruitment of the reperfusion injury salvage kinase (RISK) pathway. 
Wortmannin, an inhibitor of PI3K, and PD98059, an inhibitor of ERK, independently 
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blocked ANP mediated infarct limitation in the rabbit heart. Furthermore Yang et al. 
reported that concomitant perfusion of ODQ and ANP abrogated ANP mediated 
infarct limitation. Taken together these data strongly suggest that a pathway 
converging on sGC (PI3K/Akt/eNOS/NO/sGC) plays a critical role in NP mediated 
infarct limitation. However, biochemical confirmation of these observations is lacking. 
These studies also question whether there is a direct pGC/cGMP/PKG component to 
cytoprotective signalling or whether pGC mediated protection occurs indirectly via 
PI3K/Akt/eNOS/NO/sGC. 
Particulate guanylyl cyclase independent signalling 
Historically regarded as a clearance receptor, NPR-C is devoid of guanylyl cyclase 
coupled signalling, coupled to adenylyl cyclase inhibition through the inhibitory 
guanine nucleotide regulatory protein (Gi). NPR-C may in fact couple to signal 
transduction pathways in some cell types.104,105 Interestingly, CNP signal 
transduction via NPR-C has been shown to be cardioprotective in the rat heart.106
Surprisingly this protection was potentiated in the presence of the NOS inhibitor 
L-NAME. This observation is in contrast to that observed when concomitantly 
perfused with BNP. It remains to be determined how NPR-C signalling mediates 
infarct limitation. One possibility is that it is coupled to potassium channels as NPR-C 
activity has been linked to KIR channel opening in the mesenteric vasculature.
107 A 
second hypothetical possibility is signalling through the classical 
PI3K/Akt/NO/sGC/cGMP cytoprotective pathway. However, abrogation of the 
protection by L-NAME and no net cGMP elevation when NPR-C was targeted in rat 
aorta VSM cells108 suggests that a modified pathway is more likely. 
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Most recently a new class of so-called “designer” NPs is being developed. 
Cenderitide (CD-NP) is the first in this class of NPs which co-activates both NPR-A 
and NPR-B. It has been shown to reduce LV mass in MI-model rodents and cardiac 
unloading in dogs.109 Initial clinical trials suggest a reduction in blood pressure in 
stable heart failure patients as well as reduced creatine levels. It is proposed that 
continuous infusion of cenderitide through a subcutaneous pump will improve patient 
outcome and reduce the duration of hospital stay.110,111 Their cytoprotective benefit in 
models of myocardial ischaemia-reperfusion is yet to be explored. 
Phosphodiesterases 
Phosphodiesterase inhibition 
Maintaining cGMP levels during ischaemic insult by pharmacological manipulation of 
phosphodiesterases has been extensively investigated. The cGMP specific PDE5 
inhibitors have been utilised to explore this mechanism. A recent study has reported 
that as much as 20% of cGMP degradation in human myocytes is attributable to 
PDE5.112 Expression levels of PDE5 are increased in the failing myocardium and 
PDE5 inhibition has been shown to limit infarct size when administered prior to global 
ischaemia in a mouse model.113 The authors demonstrate that this protection is 
abolished when sildenafil was concomitantly perfused with the PKG blocker KT5823. 
They further concluded that the protection was associated with PKG-dependent 
phosphorylation of ERK, GSK3β and increased expression of the Pro survival factor 
Bcl-2.113 Early investigations demonstrated that sildenafil was cardioprotective in an 
in situ rabbit model, protection which was blocked by the KATP channel blocker 
5-HD114 and PKC inhibitor chelerythrine.115 This has been corroborated using another 
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PDE5 inhibitor vardenafil in combination with either the mitochondrial KATP channel 
blocker 5-HD or the sarcolemmal KATP channel blocker HMR1098.
116 It was later 
demonstrated that sildenafil could induce delayed preconditioning via elevation of 
both iNOS and eNOS. Protection was blocked by the iNOS inhibitor 1400W.117
Tadalafil, a PDE5 inhibitor with a longer half life was also able to limit infarct size in 
mouse 118,119 and rabbit.120 More recently, protection has been demonstrated when 
sildenafil is perfused during early reperfusion.121 The authors report that 
administration of the PDE5 inhibitor was associated with PLB Ser69 phosphorylation, 
also PKG-dependent.122 Interestingly mouse hearts subjected to 30 min global 
ischaemia followed by 10 min reperfusion with sildenafil did not elevate total cGMP 
beyond control level. This observation is corroborated by Elrod et al.123 who 
demonstrate that infarct limitation in a mouse model was independent of 
eNOS/NO/cGMP signalling and particularly that low level sildenafil (0.06 mg/kg) did 
not elevate myocardial cGMP levels. Further mechanistic studies have demonstrated 
that both sildenafil and vardenafil elicit there infarct limiting properties through a KATP
channel mediated mechanism124 and that sildenafil improves left ventricular function 
in mice.125
Regulation of specific cGMP pools 
Spatially distinct pools of cGMP are now widely accepted; however, whether these 
discrete pools mediate individual and distinct actions remains to be fully 
demonstrated. Evidence supports the notion that PDEs which are localised by 
binding of GAF domains to proteins regulate specific cGMP pools, both in their 
cellular location but also via cAMP/PKA action through PDE2/3. Castro et al.19
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reported that PKG activity can regulate cGMP concentrations in rat cardiac myocytes 
differentially via pGC and sGC. PKG activated via pGC stimulates further cGMP 
production via positive feedback, the cGMP being localised to the sarcolemma via 
PDE2 control. Conversely sGC mediated PKG activity further enhances PDE5 
activity limiting cGMP production and spatial distribution. They have previously 
demonstrated that cGMP mediated activity varies depending on whether it is 
elevated via pGC or sGC, further supporting the compartmentalisation hypothesis. 
Most recently FRET imaging in live neonatal rat cardiac myocytes expressing cGMP 
and cAMP markers has shown that sGC mediated cGMP leads to activation of 
PKA-RI via cAMP, and a reduction in PKA-RII. These opposing effects are mediated 
via PDE2/3 regulation, which are confined to specific cellular locations also. 
Interestingly cAMP activity was not elevated via ANP/pGC signalling.126 In light of 
cAMP/PKA in regulating calcium transients and inotropic effects, these observations 
may highlight further therapeutic targeting of specific cGMP/cAMP as a result of 
spatially distinct cGMP/PDE signalling. 
Conclusions 
The evidence suggests that sGC/cGMP signalling to limit infarct size is a tractable 
therapeutic target; however it is clear that mass elevation of myocardial cGMP 
concentration in itself is not required to afford protection. Live cell imaging is now 
allowing real time visualisation of cGMP whilst exposing cells to pharmacological 
interventions. This information is required to ascertain how the dynamic signals 
mediate their action following differing stimuli, which cGMP elevating targets are 
important and which cGMP compartments may be key. With this information, suitable 
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cytoprotective interventions to limit the injurious effects of ischaemia-reperfusion 
injury via cGMP signalling could be developed.  
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Figure legends/Table headings 
Figure 1 
Structural representation of natriuretic peptide receptors (NPRs) and soluble guanylyl 
cyclases (sGCs) implicated in the production of cGMP. NB. NPR-C does not have 
particulate guanylyl cyclase activity and its mechanism of possible initiation of cGMP 
production remains to be eluded. sGC exists in two redox states that can catalyse 
cGMP production, however the oxidised form of sGC has no endogenous ligand. 
Figure 2 
Schematic representation of cytoprotective signalling cascades in cardiac myocytes 
incorporating cGMP. Included is the incorporation of NO3
-/NO2
- as an alternative 
source/store of NO. Highlighted is the dynamic redox of sGC which is known to exist 
in vivo. Production of cGMP can be achieved by endogenous NO targeting the 
reduced sGC or exogenously by sGC stimulators. In addition sGC activators can 
target the oxidised state. Elevation of cGMP can also be achieved by targeting the 
membrane associated particulate guanylyl cyclase via the natriuretic peptide receptor 
ligands. cGMP is depicted in spatially distinct areas produced by different guanylyl 
cyclases and regulated by specific phosphodiesterases. Cytoprotective signalling via 
cGMP has been demonstrated to culminate in inhibition of the mPTP via reduced 
intracellular calcium concentrations and inhibition of mKATP channels. 
Table 1 
List of some of the important pharmacological agents that are able to positively 
modify cGMP concentrations. 
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Title Centre/Lead Country Start/End Drug/dose 1° end point Refs
Japan-Working Groups of Acute 
Myocardial Infarction for the Reduction 
of Necrotic Damage by KATP  (J-WIND)
National 
Cardiovascular Center,
Suita, Osaka, Japan
2005-2007 Nicorandil bolus 
followed by 24 h 
i.v.
Estimated infarct 
size 72 h
Minamino T, 
et al. 2004;
Kitakaze M, et 
al. 2007
Japan-Working Groups of Acute 
Myocardial Infarction for the Reduction 
of Necrotic Damage by KATP  (J-WIND)
National 
Cardiovascular Center,
Suita, Osaka, Japan
2005-2007 hANP 72 h i.v. Estimated infarct 
size 72 h
Minamino T, 
et al. 2004; 
Kitakaze M, et 
al. 2007
Nitric Oxide in Myocardial Infarction Size 
(NOMI)
INO Thearpeutics, USA 2006-2008 Nitric Oxide 
Inhalation
Infarct size 
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Randomized Placebo-Controlled Trial of 
Inhaled iNO in Acute ST-Segment 
Elevation MI Treated by Primary 
Angioplasty
TASMC, Israel 2009-2010 Nitric Oxide 
Inhalation 80 PPM
Infarct size 
estimated by CK 
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The Effects of Nitric Oxide for Inhalation 
on Myocardial Infarction Size
Universitaire 
Ziekenhuizen Leuven, 
Belgium
2010-2013 Nitric Oxide 
Inhalation
Infarct size 
48-72 h
Nitrites in Acute Myocardial Infarction University of 
Aberdeen, UK
2011-2014 Sodium Nitrite 2-5 
min i.v.
Infarct size 6-8 
days post
injection
Siddiqi N, et 
al. 2013
Study Evaluating the Use of Vasoldilators
to Reduce Infarct Size and Microvascular 
Obstruction in ST-Elevation MI
University Hospital 
Leicster, UK
2011-2014 Adenosine 1 mg 
via guided 
catheter
SNP 250 mcg via 
guided catheter
Infarct size 
measure by 
cardiac MRI 
48-72 h
Safety and Effectiveness of Intra-
Coronary Nitrite in Acute Myocardial 
Infarction
Barts and the London 
NHS Trust, UK
2012-2016 Sodium nitritie
bolus via intra-
coronary injection
Infarct size 
measure by 
creatine kinase
AUC 1-48 h
Jones DA, et 
al. 2013
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